Compositions and methods for increasing secretion of molecules

By employing signal peptides and truncated IbpA proteins, the secretion of therapeutic proteins is enhanced in bacterial cells, addressing the lack of effective protein display shuttles for Lachnospiraceae species and enabling effective therapeutic applications.

WO2024249677A1PCT designated stage expired Publication Date: 2024-12-05UNIVERSITY OF CHICAGO
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/031745
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-12-08
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

There is a lack of effective protein display shuttles for gut commensals, particularly for Lachnospiraceae species, which hinders the secretion of therapeutic proteins necessary for microbial therapeutics.

Method used

The use of specific signal peptides and truncated immunoglobulin binding protein A (IbpA) to enhance the secretion of molecules of interest from bacterial cells, including therapeutic proteins like IL-10 and IL-22, by linking them with a signal peptide or using genetically modified bacteria engineered with exogenous nucleic acids.

Benefits of technology

This approach significantly increases the secretion of therapeutic proteins, enabling their efficient surface presentation and bioactivity, thereby facilitating their therapeutic modalities in treating gastrointestinal disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000022_0001
    Figure IMGF000022_0001
  • Figure IMGF000026_0001
    Figure IMGF000026_0001
  • Figure 00000045_0000
    Figure 00000045_0000
Patent Text Reader

Abstract

Aspects herein relate, in part, to genetically modified bacteria capable of secreting protein of interest using signal peptides. Aspects herein also relate, in part, to presenting proteins of interest on a bacterial cell using truncated cell surface proteins.
Need to check novelty before this filing date? Find Prior Art

Description

DESCRIPTION COMPOSITIONS AND METHODS FOR INCREASING SECRETION OF MOLECULES CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority of U.S. Provisional Application Nos. 63 / 504,805 filed May 30, 2023, and 63 / 607,652 filed December 8, 2023, both of which are hereby incorporated by reference in their entirety. SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 30, 2024, is named “ARCD.P0809WO - Sequence Listing.xml” and is 9,086 kilobytes in size. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0003] This invention was made with government funding under GM147478 and DK042086 awarded by the National Institutes of Health, and 1746045 awarded by the National Science Foundation. The government has certain rights in the invention. BACKGROUND OF THE INVENTION I. Field of the invention

[0004] This invention relates to the fields of microbiology, medicine, and gene therapy. II. Background

[0005] Efficient protein secretion peptides are crucial for the development of microbial therapeutics because therapeutic proteins need to be secreted by microbial hosts to exert their function. Protein surface display is a powerful technology that involve surface presentation of recombinant proteins. The surface displayed proteins are readily accessible for interactions with surrounding environment which allows the development of engineered cells functioning as therapeutical modalities. There is no available protein display shuttles for gut commensals, Lachnospiraceae species.201636318.1 - 1 -SUMMARY OF THE INVENTION

[0006] In general, the current disclosure relates, in part, to the discovery that certain signal peptides can increase secretion of molecules of interest from bacterial cells. The current disclosure also relates, in part, to the discovery that truncations of an IbpA protein can lead to efficient cell surface presentation on bacterial cells.

[0007] Disclosed herein are nucleic acids comprising a sequence encoding a molecule of interest and / or encoding a signal peptide. In certain aspects, the sequence encodes a chimeric protein comprising a molecule of interest and the signal peptide. In some aspects, the nucleic acid encodes a molecule of interest fused to the signal peptide. The signal peptide can be a peptide that comprises a secretion domain. In certain aspects, the signal peptide increases the secretion of a molecule of interest when linked to the molecule of interest. In certain aspects, the signal peptide comprises a peptide of SEQ ID NOs:1-9.

[0008] In certain aspects, the molecule of interest is a protein, such as a human protein. In certain aspects, the molecule of interest is a plurality of proteins. In certain aspects, the molecule of interest comprises at least one therapeutic protein. In certain aspects, the molecule of interest, which may be the therapeutic protein, comprises IL-10, IL-22, GLP-2, IL-27, IL- 19, IL-20, IL-24, IL-15, IL-2, GMCSF, TNF-alpha, IFN-gamma, CXCL10, CXCL9, hyaluronidase, an anti-TNFalpha antibody, an anti-TNFalpha nanobody, an anti-IL17A antibody, an anti-IL17A nanobody, an anit-alpha4beta7 antibody, an anit-alpha4beta7 nanobody, trefoil factor-3, or a combination thereof. In certain aspects, the molecule of interest comprises a cytokine, growth factor, antibody, and / or a metabolite. In certain aspects, the molecule of interest comprises a bacterial protein. In certain aspects, the nucleic acid further comprises an inducible promoter. In certain aspects, the inducible promoter comprises pXyl, pBW-EFTU, pAH-EFTU, pER-570, pTet, pAH-570, or a combination thereof.

[0009] In certain aspects, the sequence encoding the molecule of interest and the sequence encoding the signal peptide are separated by a sequence encoding a linker. The linker may be any linker sufficient for the molecule of interest to retain its native functions and / or protein structure. In certain aspects, there is no linker separating the signal peptide and the molecule of interest. In certain aspects, the sequence encoding the molecule of interest and the sequence encoding the signal peptide are directly adjacent.

[0010] Also disclosed are nucleic acids comprising a sequence encoding a truncated immunoglobulin binding protein A (IbpA). The IbpA protein can be the IbpA protein of Accession number WP_105084811. In certain aspects, the truncated IbpA protein comprises a201636318.1 - 2 -peptide of at least 80% identity to amino acids 379-607, 510-607, 560-607, or 585-607 of a wildtype IbpA protein. In certain aspects, the truncated IbpA protein does not comprise 1, 2, 3, or 4 superantigen repeat domains of a wildtype IbpA protein. In certain aspects, the truncated IbpA protein comprises a protein starting at position 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 600, 601, 602, 603, 604, 605, 606, 607 of a wildtype IbpA protein and comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,201636318.1 - 3 -27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 600, 601, 602, 603, 604, 605, 606, 607 (or any range derivable therein) contiguous amino acids of the wildtype IbpA protein. In certain aspects, the truncated IbpA protein does not comprise amino acid 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,201636318.1 - 4 -104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 600, 601, 602, 603, 604, 605, 606, 607, or any range derivable therein, of the wildtype IbpA protein.

[0011] In certain aspects, the protein of interest comprises IL-10, IL-22, GLP-2, IL-27, IL- 19, IL-20, IL-24, IL-15, IL-2, GMCSF, TNF-alpha, IFN-gamma, CXCL10, CXCL9, hyaluronidase, an anti-TNFalpha antibody, an anti-TNFalpha nanobody, an anti-IL17A antibody, an anti-IL17A nanobody, an anit-alpha4beta7 antibody, an anit-alpha4beta7 nanobody, trefoil factor-3, or a combination thereof. In certain aspects, the nucleic acid comprising the truncated IbpA protein also comprises one or more signal peptides disclosed herein.201636318.1 - 5 -

[0012] Also disclosed are genetically modified bacteria comprising an exogenous nucleic acid, including any nucleic acid disclosed herein. In certain aspects, the bacteria comprises a human gut microbiota bacteria. In certain aspects, the bacteria comprises a commensal bacteria. In certain aspects, the bacteria comprises a pathogenic bacteria. In certain aspects, the bacteria is a Lachnospiraceae bacteria. In certain aspects, the bacteria comprises Ruminococcus gnavus and / or Coprococcus comes. In certain aspects, the bacteria comprises C. aldenense, C. clostridioforme, C. symbosium, Fusicatenibacter saccharivorans, C. scindens, Sellimonas intestinalis, C. celerecrescens, Blautia luti, Faecalicatena fissicatena, Blautia hansenii, Blautia caecimuris, Blautia glucerasea, Blautia schinkii, Coprococcus comes, Balutia faecis, R. gnavus, Roseburia intestinalis, Blautia obeum, eubacterium rectale, Blautia wexlerae, Dorea longicatena, Dorea formicigenerans, Blautia producta, Coprococcus eutactus, Tyzzerella nexilis, Anerostipes hadrus, or a combination thereof. In certain aspects, the bacteria comprises a Lachnospiraceae sp. In some aspects, the bacteria comprise a bacteria disclosed in Sorbara et al, Cell Host & Microbe, Volume 28, Issue 1, P134-146.E4, July 08, 2020, which is incorporated by reference herein in its entirety.

[0013] Also disclosed are methods of increasing secretion of a molecule of interest in a bacteria in a patient, methods of increasing a molecule of interest in a patient, methods of modulating intestinal composition of a patient by increasing a molecule of interest, methods of providing a nucleic acid to a patient, methods of providing a genetically modified bacteria to a patient, and methods of treating a patient, including treating a gastrointestinal disorder in the patient. In certain aspects, the method comprises 1, 2, 3, or more steps including administering a nucleic acid (including any nucleic acid disclosed herein) to the patient and / or administering a genetically modified bacteria (including any genetically modified bacteria disclosed herein) to the patient. In certain aspects, the patient is a human patient. In certain aspects, the molecule of interest comprises a cytokine, an antibody, a metabolite, or a molecule that is decreased in a gastrointestinal disorder. In certain aspects, the molecule of interest comprises IL-10, IL-22, and / or anti-TNFa. In certain aspects, the patient has decreased levels of the molecule of interest. In certain aspects, increasing the molecule of interest in the patient treats a disease. In certain aspects, the patient has, is suspected of having, or is diagnosed with having a disease.

[0014] Also disclosed are methods of engineering a bacteria or methods of selectively culturing a bacteria for certain characteristics. In certain aspects, the method comprises performing at least one of the following steps, which may be in any order: (a) obtaining a recipient bacteria;201636318.1 - 6 -(b) resuspending a donor bacteria comprising a nucleic acid of interest in the recipient bacteria; (c) mating the donor bacteria and recipient bacteria to generate mated bacteria; (d) plating the mated bacteria on selective media; (e) isolating single colonies of the mated bacteria; (f) grow the isolated single colonies in media; and (g) subculture the isolated single colonies with inducers.

[0015] In certain aspects, the media of (f) lacks a different bacteria, such as E. coli. In certain aspects, the donor bacteria comprises a plasmid of interest, which can be a nucleic acid disclosed herein. In certain aspects, the plasmid of interest encodes for a molecule of interest. In certain aspects, the molecule of interest comprises a signal peptide of SEQ ID NOs:1-9. In certain aspects, the molecule of interest comprises a truncated IbpA protein, including any IbpA protein disclosed herein. In certain aspects, the plasmid of interest comprises an inducible promoter. In certain aspects, the donor bacteria is E. coli. In certain aspects, the recipient bacteria is a Lachnospiraceae bacteria.

[0016] Also disclosed are genetically modified bacteria comprising an exogenous nucleic acid encoding a molecule of interest. In certain aspects, the bacteria is a Lachnospiraceae species. In certain aspects, the genetically modified bacteria is a bacteria described herein. In certain aspects, the molecule of interest is a cytokine, such as IL-22 or IL-10. In certain aspects, the cytokine is a human cytokine including human IL-22 or human IL-10. In certain aspects, the molecule of interest is a nanobody, including an anti-TNFα nanobody.

[0017] In certain aspects, the exogenous nucleic acid is integrated into the genetically modified bacteria’s genome. The integration can occur through any method disclosed herein. In certain aspects, the integration occurs through a Type II intron. In certain aspects, the genetically modified bacteria is capable of secreting the molecule of interest. In certain aspects, the exogenous nucleic acid further comprises an inducible promoter. In certain aspects, the inducible promoter is a tetracycline inducible promoter. In certain aspects, the exogenous nucleic acid further comprises a signal peptide of one of SEQ ID NOs:1-9.

[0018] Also disclosed are culture systems comprising a genetically modified bacteria, which may be any genetically modified bacteria disclosed herein. In certain aspects, the culture media comprises brain heart infusion media. In certain aspects, the culture media comprises one or more media components described herein. The culture system may be used to generate201636318.1 - 7 -molecules of interest, including any molecule of interest disclosed herein. The culture system may be used to generate molecules of interest, which are then isolated for further use. Also disclosed are supernatants collected from the culture systems disclosed herein. In some aspects, the supernatants comprise the molecule of interest, such as any molecule of interest disclosed herein including any molecule of interest fused to a signal peptide. In some aspects, the supernatant comprises the molecule of interest at an amount greater than a control. The control may be a supernatant that was not obtained through methods disclosed herein. For example, in some aspects, the supernatant comprises the molecule of interest at an amount greater than in a supernatant collected from a cell culture, where the cells do not comprise nucleic acids encoding the molecule of interest. For another example, in some aspects, the supernatant comprises the molecule of interest at an amount greater than in a supernatant collected from a cell culture, where the cells are not a Lachnospiraceae bacteria. The amount greater may be 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 times greater, or any range derivable therein, than the control amount. The amount greater may be more than 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 times greater, or any range derivable therein, than the control amount.

[0019] Throughout this application, the term “about” is used according to its plain and ordinary meaning in the area of cell and molecular biology to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0020] The use of the word “a” or “an” when used in conjunction with the term “comprising” may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Any term used in singular form also comprise plural form and vice versa.

[0021] As used herein, the terms “or” and “and / or” are utilized to describe multiple components in combination or exclusive of one another. For example, “x, y, and / or z” can refer to “x” alone, “y” alone, “z” alone, “x, y, and z,” “(x and y) or z,” “x or (y and z),” “(x and z)201636318.1 - 8 -or y,” or “x or y or z.” It is specifically contemplated that x, y, or z may be specifically excluded from an aspect or aspect.

[0022] The words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), “characterized by” (and any form of including, such as “characterized as”), or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0023] The compositions and methods for their use can “comprise,” “consist essentially of,” or “consist of” any of the ingredients or steps disclosed throughout the specification. The phrase “consisting of” excludes any element, step, or ingredient not specified. The phrase “consisting essentially of” limits the scope of described subject matter to the specified materials or steps and those that do not materially affect its basic and novel characteristics. It is contemplated that embodiments and aspects described in the context of the term “comprising” may also be implemented in the context of the term “consisting of” or “consisting essentially of.”

[0024] It is contemplated that any aspect discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.

[0025] Any method in the context of a therapeutic, diagnostic, or physiologic purpose or effect may also be described in “use” claim language such as “Use of” any compound, composition, or agent discussed herein for achieving or implementing a described therapeutic, diagnostic, or physiologic purpose or effect.

[0026] Use of the one or more sequences or compositions may be employed based on any of the methods described herein. Other aspects and embodiments are discussed throughout this application. Any embodiment or aspect discussed with respect to one aspect of the disclosure applies to other aspects of the disclosure as well and vice versa.

[0027] It is specifically contemplated that any limitation discussed with respect to one embodiment or aspect of the invention may apply to any other embodiment or aspect of the invention. Furthermore, any composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or to utilize any composition of the invention. Aspects of an embodiment set forth in the Examples are also aspects that may be implemented in the context of aspects discussed elsewhere in a different201636318.1 - 9 -Example or elsewhere in the application, such as in the Summary of the Invention, Brief Description of the Drawings, Detailed Description of the Invention, and / or Claims.

[0028] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific aspects of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0030] FIGs. 1A-1B show proteomics of secreted proteins R. gnavus. (a) SDS-PAGE analysis of cell lysate and concentrated supernatant obtained from R. gnavus. (b) Representative mass spectra obtained with cell lysate and concentrated supernatant.

[0031] FIG. 2 shows a volcano plot to compare the abundance of proteins found in the supernatant and cell lysate of R. gnavus.

[0032] FIG. 3 shows intracellular and extracellular luciferase activity of R. gnavus cells carrying plasmids that encode nanoluciferase fused with different signal peptides.

[0033] FIG. 4 shows intracellular and extracellular luciferase activity of Coprococcus comes cells carrying plasmids that encode nanoluciferase fused with different signal peptides. Left bar: Whole Cell, Right bar: Cell-Free Supernatant.

[0034] FIG. 5 shows designing IbpA protein as display shuttle for Lachnospiraceae species. Left bar: Whole Cell, Right bar: Cell-Free Supernatant.

[0035] FIG. 6 shows retained whole-cell luciferase activity of R. gnavus (left) and C. comes (right) carrying the different IbpA variants fused with nanoluciferase following the trypsin treatment. Left bar: Control, Right bar: Trypsin.

[0036] FIGs.7A-7B show a mating schematic, (a) a flow schematic for the mating scheme; (b) Gel electrophoresis of results - AC: A. caccae; AH: A. hadrus; BW: B. wexlerae; EC: E. coli; LS: Lachnospiraceae specific; ES: E. coli specific; PS: Plasmid Specific. Two plasmids (82 and 83) were used in matings, containing pBP1 and pCB102 ORIs respectively. Success indicated by bands in LS and PS lanes with no band in the ES lane.201636318.1 - 10 -

[0037] FIGs. 8A-8C shows a schematic and results for designing reporter systems, including by changing promoters. For FIG. 11C, the bacteria are Coprococcus comes (Cc), Anaerostipes hadrus (Ah), Blautia wexlerae (Bw), Anaerostipes caccae (Ac), Ruminococcus gnavus (Rg), Dorea formicigenerans (Df), and Lachnoclostridium symbiosum (Ls), left bar: wild-type, right bar: bacteria cells containing the plasmid.

[0038] FIG. 9 shows induction curves of gene expression measured after 24h incubation with anhydrotetracycline (aTc).

[0039] FIG.10 shows the experimental approach of designing certain peptides (top) to test for secretion and the experimental results (bottom) of such approach.

[0040] FIG.11 shows the experimental approach of testing certain peptides and a volcano plot of the results.

[0041] FIG.12 shows a summary of the results of certain tested signal peptides.

[0042] FIG. 13 shows signal peptide RGSS01 enables secretion in several Lachnospiraceae species. Left bar: whole cell lysate, right bar: supernatant.

[0043] FIGs. 14A-14B show engineered Lachnospiraceae species can produce bioactive mIL-22 in vitro.

[0044] FIG.15 shows C. comes secreted anti-TNF ^ Nanobodies are bioactive in vitro.

[0045] FIGs. 16A-16B show Type II introns and Cre / lox machinery allow for genomic integration of synthetic DNA into Lachnospiraceae species. Integrated DNA can be used to make knockouts or to insert new cargo.

[0046] FIG.17 shows integration of synthetic DNA improves construct stability.

[0047] FIG.18 shows engineered Lachnospiraceae species can produce mIL-10 in vitro.

[0048] FIG. 19 shows integrated mIL-22 constructs maintain production capabilities in vitro. DETAILED DESCRIPTION OF THE INVENTION I. Therapeutic Compositions

[0049] Certain aspects relate to therapeutic compositions comprising a bacteria, including any of the genetically modified bacteria disclosed herein. The bacteria may be at least one strain of any bacteria disclosed herein, including a Lachnospiraceae bacterial strain, an R. gnavus strain, and / or a C. comes strain. In some aspects, the therapeutic composition comprises, consists of, or consists essentially of the genetically engineered bacteria in a unit dosage. The unit dosage may be any dosage sufficient for the desired effect of the therapeutic composition. In some aspects the unit dosage comprises between 1×103to 9×1016colony201636318.1 - 11 -forming units (CFU) of the bacteria. In some aspects the unit dosage comprises at least, at most, or about 1×103, 2×103, 3×103, 4×103, 5×103, 6×103, 7×103, 8×103, 9×103, 1×104, 2×104, 3×104, 4×104, 5×104, 6×104, 7×104, 8×104, 9×104, 1×105, 2×105, 3×105, 4×105, 5×105, 6×105, 7×105, 8×105, 9×105, 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, 5×109, 6×109, 7×109, 8×109, 9×109, 1×1010, 2×1010, 3×1010, 4×1010, 5×1010, 6×1010, 7×1010, 8×1010, 9×1010, 1×1011, 2×1011, 3×1011, 4×1011, 5×1011, 6×1011, 7×1011, 8×1011, 9×1011, 1×1012, 2×1012, 3×1012, 4×1012, 5×1012, 6×1012, 7×1012, 8×1012, 9×1012, 1×1013, 2×1013, 3×1013, 4×1013, 5×1013, 6×1013, 7×1013, 8×1013, 9×1013, 1×1014, 2×1014, 3×1014, 4×1014, 5×1014, 6×1014, 7×1014, 8×1014, 9×1014, 1×1015, 2×1015, 3×1015, 4×1015, 5×1015, 6×1015, 7×1015, 8×1015, 9×1015, 1×1016, 2×1016, 3×1016, 4×1016, 5×1016, 6×1016, 7×1016, 8×1016, 9×1016, or any range derivable therein, CFU of the bacteria. In another aspect, the disclosure relates to compositions comprising an isolated or purified population of the bacteria. Therapeutic compositions and methods of administering the bacteria may involve such unit dosages. Moreover, a unit dosage may be given multiple times over a time period as discussed below.

[0050] Certain aspects also relate to therapeutic compositions comprising a nucleic acid, including any nucleic acid disclosed herein. In some aspects, a single dose of the nucleic acid is administered. In some aspects, multiple doses of the nucleic acid is administered. In some aspects, the nucleic acid is administered at a dose of between 1 mg / kg and 5000 mg / kg. In some aspects, the nucleic acid is administered at a dose of at least, at most, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276,201636318.1 - 12 -277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, or 5000 mg / kg.

[0051] The therapeutic compositions can be formulated for administration, including as pharmaceutical formulations, e.g., formulated for oral administration; suppository administration; or injection such as via the intravenous, intramuscular, subcutaneous, or intraperitoneal routes. Such compositions can be prepared as either liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and, the preparations can also be emulsified.

[0052] In certain aspects, the therapeutic composition, including composition comprising the genetically engineered bacteria and / or nucleic acid, is formulated for oral administration. The formulation for oral administration may comprise a pill, capsule, suspension, drink, or the like. In some aspects, the polysaccharide is administered through food.

[0053] In some aspects, the therapeutic composition, including compositions comprising the genetically modified bacteria and / or nucleic acids, is a fecal transplant. In some aspects, the fecal matter is administered in a dose of 50 g. In some embodiments, the fecal matter is administered in a dose of at least, at most, or exactly 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75.80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230,201636318.1 - 13 -240, 250, 260, 270, 280, 290, 300, 325, 350, 375, or 400 g (or any derivable range therein).In certain aspects, the fecal transplant comprises fecal matter that comprises a measurable amount of the genetically engineered bacteria. In certain aspects, the fecal transplant comprises fecal matter that comprises a therapeutically effective amount of the genetically engineered bacteria.

[0054] The pharmaceutical formulations suitable for injectable use include sterile aqueous solutions or dispersions; formulations including, for example, aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In certain aspects, the formulation is stable under the conditions of manufacture and storage and preserved against the contaminating action of non-therapeutic microorganisms.

[0055] A pharmaceutical composition or formulation can include a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. The prevention of the action of unintended microorganisms can be brought about by various anti-bacterial and anti-fungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In certain aspects, the formulation includes isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0056] Injectable solutions may be prepared by incorporating the active compounds in the required amount in the appropriate solvent with various other ingredients enumerated above, as required. In certain aspects encompassing powders for the preparation of injectable solutions, the therapeutic composition(s) are vacuum-dried and / or freeze-dried, which yield a powder of the active ingredient, plus any additional desired ingredient.

[0057] The present disclosure also provides a pharmaceutical composition comprising one or more microbial cultures as described above. The bacterial species therefore are present in the dose form as live bacteria, whether in dried, lyophilized, or sporulated form. This may be preferably adapted for suitable administration; for example, in tablet or powder form, potentially with an enteric coating, for oral treatment.

[0058] In particular aspects, the composition is formulated for oral administration. Oral administration may be achieved using a chewable formulation, a dissolving formulation, an encapsulated / coated formulation, a multi-layered lozenge (to separate active ingredients and / or active ingredients and excipients), a slow release / timed release formulation, or other suitable201636318.1 - 14 -formulations known to persons skilled in the art. Although the word “tablet” is used herein, the formulation may take a variety of physical forms that may commonly be referred to by other terms, such as lozenge, pill, capsule, or the like.

[0059] While the compositions of the present disclosure are preferably formulated for oral administration, other routes of administration can be employed, however, including, but not limited to, intracolonic, subcutaneous, intramuscular, intradermal, transdermal, intraocular, intraperitoneal, mucosal, vaginal, rectal, and intravenous.

[0060] In another aspect, the disclosed composition may be prepared as a suppository. The suppository may include but is not limited to the bacteria and one or more carriers, such as polyethylene glycol, acacia, acetylated monoglycerides, carnuba wax, cellulose acetate phthalate, corn starch, dibutyl phthalate, docusate sodium, gelatin, glycerin, iron oxides, kaolin, lactose, magnesium stearate, methyl paraben, pharmaceutical glaze, povidone, propyl paraben, sodium benzoate, sorbitan monoleate, sucrose talc, titanium dioxide, white wax and coloring agents.

[0061] In some aspects, the composition may be prepared as a tablet. The tablet may include the bacteria and one or more tableting agents (i.e., carriers), such as dibasic calcium phosphate, stearic acid, croscarmellose, silica, cellulose and cellulose coating. The tablets may be formed using a direct compression process, though those skilled in the art will appreciate that various techniques may be used to form the tablets.

[0062] In other aspects, the composition may be formed as food or drink or, alternatively, as an additive to food or drink, wherein an appropriate quantity of bacteria is added to the food or drink to render the food or drink the carrier.

[0063] The compositions of the present disclosure may further comprise one or more prebiotics known in the art, such as lactitol, inulin, or a combination thereof.

[0064] In some aspects, the composition may further comprise a food or a nutritional supplement effective to stimulate the growth of certain bacteria, including the genetically engineered bacteria, present in the gastrointestinal tract of the subject. In some aspects, the nutritional supplement is produced by a bacterium associated with a healthy human gut microbiome. II. Administration of Therapeutic Compositions

[0065] Certain aspects concern the administration of therapies and therapeutic compositions, including any therapeutic composition described herein that includes a genetically engineered bacteria. The therapies may be administered in any suitable manner201636318.1 - 15 -known in the art. The therapy provided herein may comprise administration of a combination of therapeutic composition. In some aspects, the first and second compositions are administered as separate compositions. In some aspects, the first and second compositions are administered as the same composition.

[0066] The therapeutic agents of the disclosure may be administered by the same route of administration or by different routes of administration. In some aspects, the therapeutic composition is administered intracolonically, intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In some aspects, the antibiotic is administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally. In some aspects, the composition is administered via gavage. The appropriate dosage may be determined based on the type of disease to be treated, severity and course of the disease, the clinical condition of the patient, the patient's clinical history and response to the treatment, and the discretion of the attending physician.

[0067] The treatments may include various “unit doses.” Unit dose is defined as containing a predetermined-quantity of the therapeutic composition. The quantity to be administered, and the particular route and formulation, is within the skill of determination of those in the clinical arts. A unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time. In some aspects, a unit dose comprises a single administrable dose.

[0068] The quantity to be administered, both according to number of treatments and unit dose, depends on the treatment effect desired. An effective dose is understood to refer to an amount necessary to achieve a particular effect.

[0069] Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the patient, the route of administration, the intended goal of treatment (alleviation of symptoms versus cure) and the potency, stability and toxicity of the particular therapeutic substance or other therapies a subject may be undergoing.

[0070] It will be understood by those skilled in the art and made aware that dosage units of µg / kg or mg / kg of body weight can be converted and expressed in comparable concentration units of µg / ml or mM (blood levels). It is also understood that uptake is species and organ / tissue dependent. The applicable conversion factors and physiological assumptions to be made concerning uptake and concentration measurement are well-known and would permit those of201636318.1 - 16 -skill in the art to convert one concentration measurement to another and make reasonable comparisons and conclusions regarding the doses, efficacies and results described herein.

[0071] In certain instances, it will be desirable to have multiple administrations of the composition, e.g., 2, 3, 4, 5, 6 or more (and any range derivable therein) administrations. The administrations can be at 1, 2, 3, 4, 5, 6, 7, 8, to 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 day, week, or month intervals, including all ranges there between.

[0072] The phrases “pharmaceutically acceptable” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal or human. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in immunogenic and therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-infective agents and vaccines, can also be incorporated into the compositions.

[0073] Administration of the compositions will typically be via any common route. This includes, but is not limited to oral, suppository, or intravenous administration. Alternatively, administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, or intranasal administration. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients.

[0074] The desired dose of the composition of the present disclosure may be presented in multiple (e.g., two, three, four, five, six, or more) sub-doses administered at appropriate intervals throughout the day.

[0075] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above. III. Methods of Treatment

[0076] Provided herein are methods for treating or delaying progression of certain diseases or disorders by administration of therapeutic compositions, such as compositions comprising bacteria, including a genetically modified bacteria, to a patient.201636318.1 - 17 -

[0077] The term “treatment” or “treating” means any treatment of a disease in a mammal, including: (i) preventing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition prior to the induction of the disease; (ii) suppressing the disease, that is, causing the clinical symptoms of the disease not to develop by administration of a protective composition after the inductive event but prior to the clinical appearance or reappearance of the disease; (iii) inhibiting the disease, that is, arresting the development of clinical symptoms by administration of a protective composition after their initial appearance; and / or (iv) relieving the disease, that is, causing the regression of clinical symptoms by administration of a protective composition after their initial appearance. In some aspects, the treatment may exclude prevention of the disease.

[0078] In certain aspects, the patient administered a therapeutic composition is identified as having, or is at risk of having, a disease, or disorder. In certain aspects, the patient administered a therapeutic composition is identified as having, or is at risk of having, a certain response to a treatment. The response to the treatment may be graft versus host disease. The response to the treatment may be that the patient is, or is not, responsive to a steroid therapy, including a steroid therapy administered before, during, and / or after administration of a stem cell therapy. The responsiveness to the steroid therapy may refer to the patient given a stem cell therapy being responsive or refractive to a steroid administration. The steroid therapy may be any steroid therapy administered to a patient, including prednisone, prednisolone, dexamethasone, and / or hydrocortisone. IV. Bacteria Isolation and Culture

[0079] In some aspects, bacteria, including any bacteria herein, are isolated and / or purified from a source. The bacteria may be unmodified or genetically engineered. The bacteria may be isolated and / or purified from any suitable source. In some aspects, the source is a human sample. In some aspects, the source is a non-human sample, such as a rodent sample. Bacteria may be isolated and / or purified using any method known in the art. The isolated and / or purified bacteria may then be formulated into therapeutic compositions, including the therapeutic compositions described herein. Before or after being isolated and / or purified, the bacteria may be characterized, including by sequencing to determine the composition and identity of the isolated and / or purified bacteria. The bacteria may be characterized by 16S rRNA or 23S rRNA sequencing.

[0080] In some aspects, the isolated and / or purified bacteria may be cultured for at least between about 1 days and about 40 days, for at least between about 5 days and about 35 days,201636318.1 - 18 -for at least between about 5 days and 21 days. The bacteria may be cultured to generate sufficient quantity of bacteria to reach a unit dosage. The bacteria may be cultured for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or any range derivable therein, or more days. The bacteria may be cultured in the presence of a liquid culture medium, such as an LB broth or other suitable medium for culturing bacteria. Typically, the medium may comprise a basal medium formulation as known in the art. Compositions of the above basal media are generally known in the art, and it is within the skill of one in the art to modify or modulate concentrations of media and / or media supplements as necessary for the bacteria cultured. A defined medium, however, also can be used if the growth factors, cytokines, and hormones necessary for culturing the bacteria are provided at appropriate concentrations in the medium. Media useful in the methods of the disclosure may comprise one or more compounds of interest, including, but not limited to, antibiotics, mitogenic compounds, or differentiation compounds useful for the culturing of bacteria. The bacteria may be grown at temperatures between 27° C to 40° C, such as 31° C to 37° C, or any range derivable therein, and may be in a humidified incubator.

[0081] The bacteria may be genetically modified using known techniques to introduce genetic changes to the bacteria. In certain aspects, the bacteria are genetically engineered by introducing an exogenous nucleic acid into the bacteria. The exogenous nucleic acid may include any nucleic acid described herein. V. Obtaining Nucleotides A. Synthesis

[0082] The nucleic acid molecules described herein may be generated by nucleic acid synthesis. The nucleic acids may be synthesized using any method known in the art, such as phosphoramidite synthesis and / or solid-phase synthesis. B. Expression

[0083] The nucleic acid molecules described herein may be generated by expression vectors. The expression vectors used herein may contain sequences for plasmid or virus maintenance and for cloning and expression of exogenous nucleotide sequences. Such sequences, collectively referred to as “flanking sequences” typically include one or more of the following operatively linked nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, and a selectable marker element. Such sequences and methods of using the same are well known in the art.201636318.1 - 19 -C. Expression Systems

[0084] Numerous expression systems exist that comprise at least a part or all of the expression vectors discussed above. Prokaryote-based systems can be employed for use with an aspect to produce nucleic acid sequences. Those skilled in the art are able to express a vector to produce a nucleic acid sequence using an appropriate expression system. In certain aspects, the nucleic acids are plasmids. In certain aspects, the nucleic acids are expression vectors. The nucleic acids can be introduced to a bacteria, including the genetically engineered bacteria described herein, by known methods such as transformation and / or viral delivery. D. Methods of Gene Transfer

[0085] Suitable methods for nucleic acid delivery to effect expression of compositions are anticipated to include virtually any method by which a nucleic acid (e.g., DNA, including viral and nonviral vectors) can be introduced into a cell as described herein or as would be known to one of ordinary skill in the art. Such methods include, but are not limited to, direct delivery of DNA such as by injection, by electroporation, by calcium phosphate precipitation, by using DEAE dextran followed by polyethylene glycol, by direct sonic loading, and / or by microprojectile bombardment. Other methods include viral transduction, such as by phage delivery. E. Host Cells

[0086] In another aspect, contemplated are the use of host cells into which a recombinant expression vector has been introduced. Vector DNA can be introduced into prokaryotic cells via conventional transformation or transfection techniques. Some vectors may employ control sequences that allow it to be replicated and / or expressed in both prokaryotic and eukaryotic cells. One of skill in the art would understand the conditions under which to incubate host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors.

[0087] For stable introduction into cells, it is known, depending upon the expression vector and technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die), among other methods known in the arts.201636318.1 - 20 -VI. Proteins and Signal Peptides

[0088] Certain aspects concern signal peptides useful for secreting proteins of interest. The signal peptides may be fused to a protein of interest, which can lead to an increase of secretion of the fusion. The increase in secretion may be compared to a protein that does not contain the signal peptide. The signal peptide can, in some aspects, increase secretion from a bacterium, including a Lachnospiraceae bacterium. The signal peptides may include the peptides of Table 1. Table 1: Signal Peptides. Ref Signal Peptide Sequence SEQ ID NO

[0089] As used herein, a “protein” or “polypeptide” refers to a molecule comprising at least five amino acid residues. As used herein, the term “wild-type” refers to the endogenous version of a molecule that occurs naturally in an organism. In some embodiments, wild-type versions of a protein or polypeptide are employed, however, in many embodiments of the disclosure, a modified protein or polypeptide is employed to generate an immune response. The terms described above may be used interchangeably. A “modified protein” or “modified polypeptide” or a “variant” refers to a protein or polypeptide whose chemical structure, particularly its amino acid sequence, is altered with respect to the wild-type protein or polypeptide. In some embodiments, a modified / variant protein or polypeptide has at least one modified activity or function (recognizing that proteins or polypeptides may have multiple activities or functions). It is specifically contemplated that a modified / variant protein or polypeptide may be altered with respect to one activity or function yet retain a wild-type activity or function in other respects, such as immunogenicity.

[0090] Where a protein is specifically mentioned herein, it is in general a reference to a native (wild-type) or recombinant (modified) protein or, optionally, a protein in which any signal sequence has been removed. The protein may be isolated directly from the organism of which it is native, produced by recombinant DNA / exogenous expression methods, or produced201636318.1 - 21 -by solid-phase peptide synthesis (SPPS) or other in vitro methods. In particular embodiments, there are isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences that encode a polypeptide (e.g., an antibody or fragment thereof). The term “recombinant” may be used in conjunction with a polypeptide or the name of a specific polypeptide, and this generally refers to a polypeptide produced from a nucleic acid molecule that has been manipulated in vitro or that is a replication product of such a molecule.

[0091] In certain aspects, the size of the signal peptide comprises, but is not limited to, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid residues or greater, and any range derivable therein, or derivative of a corresponding amino sequence described or referenced herein. It is contemplated that peptides may be mutated by truncation, rendering them shorter than their corresponding wild- type form, also, they might be altered by fusing or conjugating a heterologous protein or polypeptide sequence with a particular function (e.g., for biological activity, for targeting or localization, for enhanced immunogenicity, for purification purposes, etc.), including any protein disclosed herein.

[0092] The signal peptide may include 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 (or any derivable range therein) or more variant amino acids or nucleic acid substitutions or deletions, or be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable range therein) similar, identical, or homologous with at least, or at most 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35, or any range derivable therein, of SEQ ID NOs:1-9.

[0093] In some embodiments, the signal peptide may comprise amino acids 1 to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 (or any derivable range therein) of SEQ ID NOs:1-9.

[0094] In some embodiments, the signal peptide may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 (or any derivable range therein) contiguous amino acids of SEQ ID NOs:1-9.

[0095] In some embodiments, the signal peptide may comprise at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 (or any derivable range therein) contiguous amino acids of SEQ ID NOs:1-9 that are at least, at most, or exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,201636318.1 - 22 -88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable range therein) similar, identical, or homologous with one of SEQ ID NOS:1-9.

[0096] In some aspects, the signal peptide starts at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34, of any of SEQ ID NOS:1-9 and comprising at least, at most, or exactly 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 (or any derivable range therein) contiguous amino acids or nucleotides of any of SEQ ID NOS:1-9.

[0097] Certain aspects concern molecules of interest, which can be a protein including any protein disclosed herein, conjugated to a signal peptide, including any signal peptide disclosed herein. The molecule of interest may be a therapeutic protein. In some aspects, the signal peptide and molecule of interest are comprised in a therapeutic composition.

[0098] The nucleotide as well as the protein, polypeptide, and peptide sequences for various genes have been previously disclosed, and may be found in the recognized computerized databases. Two commonly used databases are the National Center for Biotechnology Information’s Genbank and GenPept databases (on the World Wide Web at ncbi.nlm.nih.gov / ) and The Universal Protein Resource (UniProt; on the World Wide Web at uniprot.org). The coding regions for these genes may be amplified and / or expressed using the techniques disclosed herein or as would be known to those of ordinary skill in the art.

[0099] It is contemplated that in compositions of the disclosure, there is between about 0.001 mg and about 10 mg of total polypeptide, peptide, and / or protein per ml. The concentration of protein in a composition can be about, at least about or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or more (or any range derivable therein). Examples

[0100] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. Example 1: Signal Peptides for protein secretion in Lachno species201636318.1 - 23 -

[0101] To find the efficient protein secretion peptides, we screened candidate signal peptides using nano-luciferase enzyme assay. Three different strategies were employed to determine candidate signal peptides. In the first strategy, a proteomics study was carried out to identify secreted proteins during in vitro growth of Ruminococcus gnavus (RG), which serves as our representative model for the Lachnospiraceae species. The second strategy involved a meticulous manual review of existing literature related to RG to ascertain proteins whose secretion had been experimentally validated in previous studies. In the third strategy, we harnessed bioinformatic tools to analyze the RG genome, seeking out all potential signal peptides. This information was then leveraged to create synthetic signal peptides through alignment of the identified sec pathway signal peptide candidates.

[0102] Selected signal peptides were cloned upstream of the nano-luciferase enzyme in the conjugation vector with an expression cassette for lachnospiraceae species. The sequence verified plasmids were conjugated into RG. The plasmid conjugation was verified with PCR. RG cells carrying the expression plasmids were grown and induced for protein expression. Following the induction, cells were collected, and the luciferase activity of cell-free supernatant and cells were measured to determine the most efficient signal peptide in RG. The signal peptides were screened in Coprococcus comes (CC) to assess their protein secretion efficiency.

[0103] In the first strategy, secreted proteins from RG organism during its in vitro growth were determined using mass spectroscopy. RG cells were grown in YPG media (Anaerobic Systems) that doesn’t contain heme. After the growth, cell free supernatant was obtained via centrifugation and concentrated using an ultrafiltration tube by 100x fold. Cell pellets were washed with PBS; subsequently, were lysed with lysis buffer (SDS lysis buffer (%5 SDS, 50mM TEAB, pH 7.55). An SDS-PAGE gel was run to check protein bands before MS analysis. Clear proteins were observed for both concentrated supernatant and cell lysate. (FIG. 1A) Proteins present in cell lysate and concentrated supernatant were determined using mass- spectroscopy. (FIG.1B) A volcano plot was drawn to compare proteins that appeared both in the supernatant and cell lysate. (FIG.2) Proteins whose quantity significantly was enriched in the supernatant fraction compared to cell lysate and proteins that was only found in supernatant fractions were selected and their signal peptides were tested. In total five different signal peptides were selected from MS analysis. (FIGs.1A, 1B, 2).

[0104] In the second strategy, literature was manually searched for the proteins whose secretion is experimentally validated and their signal peptides were selected for recombinant protein secretion. Two signal peptides were found to be translocated in the supernatant by studies in the literature. (Bunker vd., 2019; Tailford vd., 2015)201636318.1 - 24 -

[0105] In the last strategy, Glam2 motif finder was used to find conserved motifs among the sec signal peptides determined in the third strategy. (Frith vd., 2008) A synthetic sec translocation signal peptide was constructed based on the alignment. RefUniprotAnnotation Source Signal Peptide Sequence201636318.1 - 25 -

[0106] Ruminococcus gnavus VPI C7-9 (ATCC-29149) strain was used in the initial screening of selected signal peptides since DNA conjugation using E. coli donor was previously shown. (Bell et al, 2019) A modified conjugation protocol developed by Heap et al (2009) was performed with E. coli S17 donor strain for DNA transfer into RG. (Heap et al, 2009) The conjugative plasmids used in the experiments contain an E. coli origin of replication, gram positive replicon (pCB102), catP cassette for chloramphenicol resistance, oriT for conjugation and full expression cassette inducible with aTc.

[0107] For conjugation into R. gnavus, plasmids were transformed into E. coli S17 strain with chemical transformation. Both recipient R. gnavus cells and E. coli S17 cells that carry the plasmid to be conjugated were grown overnight. On the day of conjugation, 1 ml of E. coli cells were collected with centrifugation at 4500xg for 5 minutes and washed with 1x PBS supplemented with 0.05% cysteine. After that, the cell pellet was transferred into the anaerobic growth chamber. Two additional PBS washes were performed with a pre-reduced solution in the chamber. Following the washing steps, 250µl of R. gnavus grown anaerobically in BHIS media was mixed with E. coli pellet. The cell suspension was dropped onto a prereduced BHIS agar plate without any antibiotics. The bacterial lawn was grown for one day. Next day, all bacterial lawn was collected by scraping and dissolved in the prereduced 500µl of cysteine- supplemented PBS.250µl of cell suspension was spread onto BHIS agar plate supplemented with 60 µg / ml kanamycin and 10 µg / ml thiamphenicol instead of chloramphenicol. Plates were incubated at 37 ˚C for 2 days. After the incubation, single colonies were picked and streaked onto new antibiotic-supplemented BHIS plate with X-gal and incubated for 2 days to visualize conjugant colonies.

[0108] RG cells carrying the plasmids were grown and induced to express nanoluciferase with signal peptides. To induce the protein expression, signal colonies were picked and grown overnight in the prereduced BHIS liquid media supplemented with kanamycin and thiamphenicol. The next day, cells were diluted 100-fold into fresh media with 100ng / ml aTc and antibiotics and grown overnight again. Following the induction, 200µl of cells were transferred into 96-well plate and centrifuged for 30 minutes at 4500xrpm to obtain cell free supernatant and cell pellet. Cell pellet was suspended in 200µl of PBS. To measure the nanoluciferase activity, NanoGlo kit (Promega) was used. Before measurement, both cell suspension in PBS and cell free supernatant was diluted 10-fold to prevent saturation during the measurement.

[0109] Luminescence measurement revealed that extracellular nanoluciferase activity was higher than intracellular control with all peptides except ssREA12. The highest extracellular201636318.1 - 26 -activity was obtained with ssJack-1, ssREA11 and ssREA14 peptides meanwhile ssREA14 peptide had the highest ratio of supernatant-to-intracellular luciferase activity thereby which indicates the highest extracellular protein translocation efficiency (FIG.3).

[0110] Following the testing of the signal peptides with R. gnavus, all plasmids were conjugated into butyrate producing Lachnospiraceae species. We obtained single colonies for Coprococcus comes strain after conjugation with the unmodified protocol. Conjugated CC cells were induced for protein expression, and extracellular and intracellular luminescence activities were determined. Both procedures were carried out same as described above. According to activity results, performances of signal peptides were identical in CC cells as in RG cells (FIG. 4). Example 2: Protein Display Shuttle for Lachno Species

[0111] Therefore, a protein display shuttle was engineered and optimized for Lachnospiraceae species to facilitate the extracellular presentation of membrane-bound proteins. To do so, IbpA protein was truncated gradually while retaining its native signal peptide, to evaluate the display efficiency of each variant. IbpA is an extracellular membrane bound protein identified in R. gnavus and possesses four repeats of a superantigen domain and a sortase motif at its C-terminal. (Bunker et al, 2019)

[0112] During the truncation process, the N-terminal signal peptide was kept same; meanwhile, all superantigen domains were removed from the protein sequence. As a cargo protein, nanoluciferase was fused downstream of signal peptide with a flexible linker. Subsequently, the remaining portion of IbpA, devoid of superantigen domains, was fused downstream of nanoluciferase. Four different variants of IbpA were constructed by progressively truncating the remaining IbpA sequence downstream of the nanoluciferase (FIG. 5).

[0113] All IbpA variants were conjugated to both R. gnavus and C. comes to test the extracellular protein display. Cells were induced and centrifuged to obtain cell pellet. To test protein display, cells were treated with trypsin (%0.025) for one hour at 37˚C. Following the incubation, cells were washed with PBS for two times and their whole cell luciferase activity was assessed same as described above and compared with untreated cells. Whole cell luciferase activities revealed that cells carrying 379-607 and 510-607 variants could display proteins on the cell surface because cells carrying those plasmids lost their luciferase activity drastically after the trypsin assay (FIG.6).201636318.1 - 27 -Example 3: Directing Lachnospiraceae biosynthesis with novel genetic tools

[0114] The Human Microbiome & Disease

[0115] Changes in microbiome diversity have been associated with many disease states. Correlative studies link microbiome perturbation to the onset of various diseases. Native Lachnospiraceae administration can prevent the onset of some diseases in vivo. Anaerostipes caccae of the Lachnospiraceae family (Clostridia XIVa) is protective against the onset of a BLG-mediated allergy disease state.

[0116] Engineering Native Gut Microbes

[0117] Investigating Lachnospiraceae from microbiome studies allows for development of tools to interrogate bacterial mechanisms of protection, augmenting beneficial native chassis for payload delivery, and engineer systems to monitor and respond to intestinal perturbations.

[0118] Using synthetic biology for commensal engineering allows for the use of modular parts to enable control of molecular metabolism and the delivery of synthetic payloads, use of resident microbes as a unique knob to tune host responses, and blueprint toolkits for other intractable microorganisms.

[0119] Engineering Lachnospiraceae Plasmid-Based Tools

[0120] Novel mating scheme enables the transfer genetic of genetic material to previously intractable members of the Lachnospiraceae family (FIGs.7A-7B). To transfer genetic material from donor E. coli S17 ^ pir to Lachnospiraceae species, conjugative mating strategies were adapted from Sheridan et al. 2019 (Anaerobe 59, 131–140 (2019)). Prior to mating, plates containing supplemented BHI agar (BHIS) containing 0.05% cysteine-HCl as a reducing agent were added to the anaerobic chamber and allowed to reduce at least 4 hours for optimal mating conditions. Following successful construction of shuttle vectors, saturated overnight cultures in selective media of E. coli containing cargo DNA are diluted 1:100 in fresh selective media and grown for approximately 4 hours to reach OD600of 0.4-0.6. Concurrently, saturated overnight cultures of recipient Lachnospiraceae species are diluted 1:100 and grown for approximately 4 hours to reach OD600of 0.4-0.6. Once reached, 1mL of donor E. coli culture is centrifuged for 5 minutes at 5000xg. The supernatant is discarded, and the donor pellet is transferred to the COY Systems anaerobic chamber where it is washed twice with anaerobic PBS containing 0.05% cysteine-HCl (centrifugation at 5000xg for 5 minutes). After washing, 250 uL of Lachnospiraceae recipient culture is used to resuspend the E. coli donor pellet and the entire suspension is carefully added to reduced BHIS plates in a single spot and rested at room temperature for at least 30 minutes to allow for the spot to dry. Mating plates are then201636318.1 - 28 -incubated anaerobically at 37C anaerobically for 18-24 hours. Following incubation, mating spots are scraped using sterile 1uL inoculation loops into 500 uL of anaerobic PBS and suspended by aspiration. After a homogenous suspension is achieved, 250 uL of the suspended mating is plated on reduced selective BHIS plates containing 5 ug / mL Thiamphenicol and 60 ug / mL Kanamycin and plates are incubated at 37C for 24-72 hours to allow colonies to appear. After colonies appear on selective plates, individual colonies are selected using a sterile inoculation loop and streaked onto fresh reduced selective BHIS plates to isolate single colonies. Isolation plates are incubated anaerobically at 37C for 24-72 hours and isolated colonies are grown in reduced selective BHIS media anaerobically at 37C for 24-72 hours. Colony PCR with GOTaq2 is used to confirm the successful transfer of genetic material.

[0121] Developing Functional Reporter Systems

[0122] Reporter systems were developed for use in bacterial compositions. Transferring synthetic genetic cargo to bacteria is essential for developing tools to understand their molecular underpinnings as well as for the development of microbial therapeutics. Furthermore, to create and test these genetic systems, the use of a reporter protein greatly streamlines these investigations.

[0123] For preliminary development of genetic systems, a NanoLuc1protein was codon optimized for Clostridium acetobutylicum ATCC 824 using the IDT Codon Optimization Tool. This sequence was synthesized into a gBlock from IDT and co-assembled into pMTL831512with putative promoter regions upstream housekeeping genes in Lachnospiraceae species (EF- Tu B. wexlerae – pJHA108, EF-Tu A. hadrus – pJHA104, ^70 E. rectale – pJHA106, ^70 A. hadrus – pJHA105) or published promoter sequences for Clostridium dificle (pXyl3- pJHA180, pTet4– pJHA166) using Gibson assembly. Resulting plasmids were cloned int E. coli S17 ^ pir- cells and transferred into Lachnospiraceae using a modified mating protocol from Sheridan et al., 20195. For proof-of-concept measurements, constructed plasmids were mated into R. gnavus and verified using sanger sequencing. Single isolated colonies of R. gnavus containing NanoLuc expression plasmids were grown to saturation in BHIS containing Thiamphenicol and Kanamycin and NanoLuc expression was measured using NanoGlo.

[0124] From Luminescence measurements, pAH-S70 ( ^70 A. hadrus) appeared to have the greatest expression strength of tested promoters when compared to the wild-type (grey) (FIG. 8B.) and therefore this construct was used to assess NanoLuc functionality in other species of Lachnospiraceae. Following the same mating protocol, a plasmid containing pAH- S70-NanoLuc was transferred to several species of Lachnospiraceae including Coprococcus201636318.1 - 29 -comes (Cc), Anaerostipes hadrus (Ah), Blautia wexlerae (Bw), Anaerostipes caccae (Ac), Ruminococcus gnavus (Rg), Dorea formicigenerans (Df), and Lachnoclostridium symbiosum (Ls). Luminescence was likewise measured using NanoGlo and resulting measurements indicated that bacterial cells containing the plasmid (green) are able to express functional NanoLuc while wild-type cells (grey) are unable to convert the NanoLuc substrate into a luminescent product (FIG.8C).

[0125] Tuning Genetic Tools

[0126] Inducible promoters allow for tuned response of gene expression and exogenous control of cargo protein production (FIG.9).

[0127] Designing Lachnospiraceae Secretion Systems

[0128] SignalP was used to generate a library consisting of full-length secreted peptide- NanoLuc fusions and minimal signal sequence-NanoLuc fusions to assess secretion capabilities of native proteins (FIG. 10). Proteomics analysis of supernatant and cellular fractions revealed differentially abundant proteins which could be tested for signal peptide activity (FIG.11)

[0129] Proteins found in supernatant fractions were extracted to created a proteomics- based library of signal peptides (FIG.12). Example 4: RGSS01 Signal Peptide

[0130] With the advent of transferring genetic cargo to Lachnospiraceae species, the development of efficient secretion systems to enable the export of such protein cargos without cellular lysis is of great importance. In addition to the development of multiple signal peptides, functional secretion systems across multiple species of the Lachnospiraceae family can unlock protein production from species with unique biosynthetic pathways. From a genome-wide screen of Ruminococcus gnavus VPI C7-9 CDS, potential signal peptides were identified using SignalP 6.09, and RGSS01 (sequence: MRKKQKNGMLQKMLMAAVFLLVLTVIPPQTARAA (SEQ ID NO:9)) was identified as a promising candidate to secrete over 50% of reporter protein NanoLuc in vitro from C. comes and R. gnavus. To assess the efficiency of this secretion system in other Lachnospiraceae species, a construct containing an inducible version of either RGSS01-NanoLuc (pJHA521) or NanoLuc only (pJHA272) only as an intracellular control was transferred to 5 species of Lachnospiraceae including Coprococus eutactus (Ce), [Clostridium] symbiosum (Cs), Anaerostipes hadrus (Ah), [Ruminococcus] gnavus (Rg), and Coprococcus comes (Cc). Cells were grown to saturation in BHIS containing Thiamphenicol and Kanamycin and the following201636318.1 - 30 -day were diluted 1:100 in fresh media containing the same antibiotics and 100 ng / mL aTc and grown for 4-6 hours. Supernatants were collected from cultures by centrifugation at 4,500 rpm for 15 minutes and resultant pellets were washed in PBS and resuspended in an equal volume of PBS to collected cultures. Luminescence was measuring using the NanoGlo assay (Promega) on a Tecan infinite 200 plate reader.

[0131] Measurements indicate that for Cs, Ah, Rg, and Cc, a higher proportion of supernatant: cell pellet luminescence is observed in cells containing constructs with RGSS01, whereas for Ce it appears that there is no significant change between intracellular and RGSS01 groups (FIG. 6). This suggests that while NanoLuc is produced and functional, due to luminescence increases from the media control group, RGSS01 provides no additional secretion benefit to measurable supernatant NanoLuc beyond what can be detected from spontaneous lysis events. Example 5: Plasmid Construction Constitutive promoter plasmids

[0132] To construct plasmid pJHA105, a 3-piece Gibson assembly was performed following standard procedures1. The 167 bp region upstream of sigma70 gene (locus: NAGOKMPI_02529) from Anaerostipes hadrus DSM 3319 was extracted via PCR as a putative promoter region and cloned upstream of the NanoLuc coding sequence2, which was first was codon optimized for Clostridium acetobutylicum ATCC 824 using the IDT Codon Optimization Tool, and both parts were subsequently cloned into pMTL83151 vector3into the lacZ alpha fragment between BamHI and HindIII restriction endonuclease sites.

[0133] Plasmids containing other promoter regions were constructed via Gibson assembly by extracting promoter regions from Blautia wexlerae (pBW-EFTU) Anaerostipes hadrus (pAH-EFTU), Eubacterium rectale (pER-S70), pJK024(pTet), or pIA335(pXyl). Inducible promoter plasmids

[0134] To construct plasmid pJHA272, a 2-piece Gibson assembly was performed following standard procedures1. The TetR-pTetA regulator-promoter region was extracted via PCR from plasmid pJK024and cloned into pJHA105 (this work) replacing the pAHS70 promoter region.

[0135] To construct plasmids containing signal peptides, signal sequences were synthesized into primers (IDT) and cloned using around-the-horn cloning techniques. Full-201636318.1 - 31 -length signal peptide fusions were cloned by extracting signal sequence-secreted peptide DNA from purified Ruminococcus gnavus genomic DNA and performing Gibson assembly using standard techniques. Plasmids with bioactive protein cargos

[0136] To construct plasmids containing protein cargos, a 2-piece Gibson assembly was performed following standard procedures1. The sequence of mIL22 (peprotech), mIL10 (peprotech), or anti-TNF ^ nanobody was first was codon optimized for Clostridium acetobutylicum ATCC 824 using the IDT Codon Optimization Tool then synthesized as a gBlock (IDT) before subsequent cloning into pJHA521 (this work) to replace the NanoLuc coding sequence downstream of the RGSS01 signal sequence or into pJHA272 (this work) in the case of intracellular controls. Plasmids containing type-II intron machinery

[0137] To construct plasmids containing type II intron machinery, a lox66 attB site was added to the plasmid pQint6, based on positioning in the plasmid pQlox667via around-the-horn PCR to construct plasmid pJHA275.

[0138] To target chromosomal regions of Lachnospiraceae species, retargeted intron sequences were ordered as gBlocks from IDT and cloned into pJHA275 (this work). Retargeted intron sequences were designed using the ClosTron design tool8using the Perutka method. This method was used to create plasmids for both knockdown and landing pad strain engineering.

[0139] To create cre recombinase-based insertion vectors, plasmid pJHA789 was constructed via 4-piece Gibson assembly using the origin RP4 / RSK from pAT8902, the pAH- S70 promoter, a gBlock containing codon optimized cre recombinase7(Clostridium acetobutylicum ATCC 824, IDT codon optimization tool) and the lox71 attP site and random spacers which was inserted downstream of the pAH-S70 promoter, and the catP antibiotic resistance gene (pJHA105, this study).

[0140] A inducible NanoLuc was subsequently added to pJHA789 to create pJHA830 by 2-piece Gibson assembly of TetR-pTetA-NanoLuc flanked by terminator regions from pJHA272 into the spacer region downstream of the lox71 attP site.

[0141] Bioactive protein cargo (with or without signal sequences) was added to pJHA830 via Gibson assembly to replace the NanoLuc coding sequence.201636318.1 - 32 -Example 6: Engineering Lachnospiraceae species

[0142] To prepare mIL-22 samples, C. comes cells containing plasmid pJHA613 were grown to saturation in supplemented brain heart infusion media (BHIS: BHI + Hemin + Vitamin K3+ Cysteine-HCl + ATCC trace mineral supplement) containing 5 ug / mL thiamphenicol and 60 ug / mL kanamycin. Protein expression was induced by adding 100ng / mL anhydrous tetracycline (aTc) to cells diluted 1:100 in fresh media and subsequently culturing cells at 37C for 4-6 hours to reach mid-log phase. Supernatants were collected from C. comes cultures via centrifugation for 15 minutes at 4,500 rpm. Protein concentration was analyzed by DuoSet ELISA (R&D systems) and samples were diluted 1:100 in reagent diluent 3 (R&D systems) to avoid oversaturation of plate reader measurements.

[0143] ELISA measurements indicate wild-type C. comes do not produce measurable mIL- 22 in their supernatant fraction, while C. comes containing the mIL-22 gene on plasmid pJHA613 produce detectable amounts of mIL-22 in their supernatant fraction (FIG. 1A). Furthermore, aTc induction increases mIL-22 concentration by approximately 20-fold, resulting in a final concentration of roughly 200 ng / mL of mIL-22 from C. comes.

[0144] For therapeutic applications protein cargo secreted from Lachnospiraceae must modify host tissue signaling pathways. To test bioactivity for murine IL-22 (mIL-22) secreted from Coprococcus comes, an in vitro assay using human derived HT-29MTX epithelial cells was designed to detect mIL-22-mediated phosphorylation of STAT3. As HT-29MTX cells express the heterodimeric receptor for human IL-22 consisting of IL-10R2 and IL-22R1, signaling through Tky2 and Jak kinases respectively to phosphorylate STAT3, HT-29MTX cells provide an ideal litmus for mIL-22 activity as mIL-22 is known to cross react with human receptors.

[0145] In this assay, HT-29MTX cells were prepared using standard culture techniques to reach 90% confluency, seeded one day prior to the assay at a concentration of 6.75x105cells per well in a 6-well plate and starved for 4-6h in DMEM without serum supplementation. To prepare mIL-22 samples, C. comes supernatants were collected from C. comes cultures as before and diluted in 50 uL PBS to a final concentration of 40 ng / mL secreted mIL-22 based on concentrations measured from ELISA (FIG. 14A) or an equal volume of bacterial supernatant for the wild-type and intracellular controls. IL-22 standards (Peprotech) were prepared by dilution in PBS. Once samples and standards were prepared, they were further diluted 1:4 in DMEM without serum supplementation to a final volume of 200uL and added to prepared HT-29MTX cells, where they were cultured for 15 minutes, washed in PBS and201636318.1 - 33 -transferred onto ice for lysis. Cellular lysis was performed using RIPA buffer (RIPA, micro- cOmplete protease inhibitor, HALT phosphotase inhibitor) on ice for 20 minutes, and cellular debris was pelleted by scraping cells into microcentrifuge tubes and centrifugation for 10 minutes at 15,000 x g. Resulting supernatant was transferred to a new microcentrifuge tube and the protein concentration was determined via BCA.

[0146] Western blots of cell lysate was performed to visualize the phosphorylation of STAT3. Samples were normalized to 10 ug in Laemmli buffer containing ^-mercaptoethanol and boiled for 10 minutes. Mini-PROTEAN 4-15% gels were loaded with samples for separation at 300V for 15 minutes in Tris-SDS-glycine buffer and protein was transferred to a nitrocellulose membrane using Tris-glycine-methanol buffer for 60 minutes at 60V. Protein- containing membranes were blocked at room temperature for 2 hours in 5% milk in TBS with 0.05% Tween 20 (TBST). Primary incubation of 1:1000 Rb anti-Phospho-STAT3 (Tyr705) (Cell Signaling Technologies) was conducted overnight at 4C in 5% BSA in TBST and secondary incubation of 1:5000 Goat anti-Rb IgG-HRP was conducted in 5% BSA in TBST for 1 hour. Following primary and secondary incubation, blots were washed 3 times in TBST for at least 5 minutes per wash. Blots were developed using Clarity ECL chemiluminescent substrate for 5 minutes (Bio-Rad) and imaged using a Bio-Rad Gel Doc. Blots were stripped using Restore PLUS stripping buffer (Thermo) and washed times in TBST before re-blocking in 5% milk in TBST at room temperature for 2 hours. Blots were re-probed using Rb anti- STAT3 in 5% milk in TBST overnight at 4C. Secondary probing using Goat anti-Rb IgG-HRP was performed at room temperature for 1 hour and blots were washed and imaged in the same manner as for anti-Phospho-STAT3 blots.

[0147] Image analysis of western blots indicated that HT-29MTX cells exposed in vitro to purified mIL-22 in PBS or bacterial supernatants from C. comes producing secreted mIL-22 (pJHA613) but not C. comes producing mIL-22 intracellularly (pJHA612) were able to phosphorylate STAT3 into phosphor-STAT3 (p-STAT3) (FIG. 14B). All treated cells had similar band patterning and intensity for STAT3, indicating that Jak / Tyk2 kinase activity was due to activation via mIL-22 from C. comes supernatants and C. comes itself, as well as supernatant from C. comes producing non-secreted mIL-22, is insufficient to activate this phosphorylation pathway.

[0148] In addition to testing the bioactivity of mIL-22 in vitro, C. comes producing anti- TNF ^ nanobodies was similarly evaluated for its ability to function on mammalian tissue in vitro. To test anti-TNF ^ bioactivity, a modified TNF ^ sensitivity assay was performed using201636318.1 - 34 -HEK-Blue TNF ^ (Inviogen) cells was performed. In this assay, HEK-Blue TNF ^ produce secreted alkaline phosphatase (SEAP) in response to TNF ^ signaling. By adding anti-TNF ^ nanobodies, this signal can be dampened, indicating bioactivity.

[0149] For this assay, HEK-Blue TNF ^ cells were grown using standard culture techniques to 90% confluency in DMEM with serum supplementation. Cells were seeded at 5x104cells per well in a 96-well tissue culture plate 24 hours before assay measurement alongside samples and standards before incubation at 37C. Samples were prepared by centrifugation for 15 minutes at 4,500 rpm of wild-type C. comes or C. comes producing intracellular (pJHA614 and pJHA616) and secreted versions of anti- TNF ^ nanobodies containing either a 3x Glycine- Serine linker between the VHH regions or a Hinge linker connecting these fragments, pJHA615 or pJHA617 respectively. C. comes cultures were similarly prepared and induced as mIL-22 producing C. comes before supernatant collection. Samples from C. comes were added to seeded HEK-Blue TNF ^ cells in a 4:1 ratio of DMEM with serum supplementation containing 1 ng / mL TNF ^ (peprotech): bacterial supernatant for a total volume of 100 uL. TNF ^ was directly dissolved in serum-supplemented DMEM to create a standard curve. After a 24hour incubation, 24 uL of supernatant from HEK-Blue TNF ^ cells is added to 180 uL of Quanti- Blue solution (Invivogen) and OD622is measured to assess TNF ^ activity.

[0150] Optical density measurements at 622nm reveal that while wild-type C. comes is able to dampen TNF ^ signaling, C. comes producing anti-TNF ^ nanobodies intracellularly or extracellularly can dampen TNF ^ signaling to a greater degree (FIG. 15). Interestingly, significant additional dampening of TNF ^ activity is not observed for secreted anti-TNF ^ nanobodies as compared to intracellularly produced nanobodies. Furthermore, the choice of VHH linkage appears to have little bearing on the dampening effect seen by C. comes produced anti-TNF ^ nanobodies.

[0151] As a useful genetic tool, type II introns can be utilized for creating genetic knockouts in Lachnospiraceae species. Retargeted introns designed with ClosTron targeting a specific gene can be designed and cloned into E. coli and subsequently mated into Lachnospiraceae species (pJHA342). PCR is used to first confirm these integrations into a genomic locus in R. gnavus, creating a functional knockout of Rnga_00694, a bile-acid dehydrogenase. Using a flanking primer pair, a gel image reveals the insertion of approximately 1kb into the gene, which can disrupt translation by inserting early stop codons (FIG.16A).

[0152] Further, while plasmid systems are advantageous for rapidly prototyping synthetic genetic cargo, they are limited in their long-term applications due to stability and201636318.1 - 35 -biocontainment concerns. Type II introns provide an intriguing alternative to plasmid-based systems as they can incorporate lox sites into genomic loci to create a “landing-pad” for cre / lox- based recombination and insertion of synthetic cargo directly into bacterial genomes6,7. Using ClosTron design tools8, re-targeted type II introns were designed to insert a lox66 site into an intergenic region of the C. comes genome (pJHA787), to allow for the creation of a landing- pad strain while attempting to minimize disruptions to the endogenous C. comes transcriptome. After confirming the creation of such a strain with sanger sequencing, a complementary plasmid containing the cre recombinase under the control of the pAH-s70 promoter and incorporating a lox71 site and a spacer insertion site was designed and synthesized using Gibson assembly (pJHA789). By adding inducible NanoLuc into the insertion site on this plasmid to create pJHA830, cre / lox recombination between cognate lox66 and lox71 sites allow for the incorporation of the NanoLuc gene directly into the genome of C. comes. PCR reveals that a lox site is first inserted into wild-type C. comes (FIG.16B). Then using a different set of primers, it is revealed that a cre / lox plasmid can be inserted into the genome, resulting in a band where amplification of the lox landing pad strain contains none. Finally, using PCR the insertion of a NanoLuc protein sequence can be observed alongside the plasmid insertion band, however due to its large size, the entire locus cannot be readily visualized via colony PCR. Following PCR, sanger sequencing provides confirmation that a cre / lox-NanoLuc plasmid can be successfully inserted into a lox containing landing-pad strain.

[0153] To investigate the stability of genomic integration, plasmid maintenance can be assessed by serial passaging of a plasmid-NanoLuc or an integrated-NanoLuc strain on BHIS agar with or without antibiotic supplementation.

[0154] In this assay, C. comes containing either plasmid (pJHA272) or integrated NanoLuc (pJHA830) was first grown to saturation in triplicate. Then, the NanoGlo assay was used to measure the Luminescence of saturated cultures, which were then diluted 1:00 in fresh media with or without antibiotics. This process is then repeated 7 times to monitor the stability of the NanoLuc construct in non-selective BHIS as compared to BHIS containing antibiotics. The resulting measurements indicate that C. comes containing NanoLuc on a plasmid rapidly lose the ability to convert the NanoLuc substrate into a luminescent product, while C. comes with genomically integrated NanoLuc maintains enzymatic capability for more passages and to a higher degree (FIG.17).

[0155] To prepare mIL-10 samples, R.gnavus, L. symbiosum, or C. comes cells containing either inducible mIL10 (pJHA610) or ss-mIL10 (pJHA611) were grown to saturation in supplemented brain heart infusion media (BHIS: BHI + Hemin + Vitamin K3 + Cysteine-HCl201636318.1 - 36 -+ ATCC trace mineral supplement) containing 5 ug / mL thiamphenicol and 60 ug / mL kanamycin. Protein expression was induced by adding 100ng / mL anhydrous tetracycline (aTc) to cells diluted 1:100 in fresh media and subsequently culturing cells at 37C for 4-6 hours to reach mid-log phase. Supernatants were collected from bacterial cultures via centrifugation for 15 minutes at 4,500 rpm. Protein concentration was analyzed by DuoSet ELISA (R&D systems).

[0156] ELISA measurements indicate no wild-type bacteria produce measurable mIL-10 in their supernatant fraction, while only R. gnavus and C. comes containing the mIL-10 gene on a plasmid produce detectable amounts of mIL-10 in their supernatant fraction (FIG.18).

[0157] After a lox site is inserted into the genome of C. comes a plasmid containing a cognate lox site and a cre recombinase can be mated into C. comes to insert genetic cargo. Using a constructed strain of C. comes containing an intergenic lox site, a cognate cre / lox plasmid containing mIL-22 (pJHA848 and pJHA843 – replicates) is mated into this landing- pad strain to insert mIL-22 into the C. comes genome. After verification via sanger sequencing, isolated C. comes colonies with genomically integrated mIL-22 or C. comes containing mIL- 22 on a plasmid (pJHA613 + ctrl) are grown in BHIS with antibiotics until saturation and subsequently diluted into fresh BHIS containing antibiotics and 100 ng / mL aTc. After 4-6 hours supernatants are collected via centrifugation for 15 minutes at 4,500 rpm and mIL-22 concentration is measured using the DuoSet mIL-22 ELISA (R&D systems).

[0158] Measurements of mIL-22 in C. comes supernatant indicate that genomically integrated mIL-22 is produced at approximately the same concentration as mIL-22 expressed on a plasmid (FIG. 19). This suggests that genomic integration is a viable technique for improving the stability of synthetic genetic constructs without significantly decreasing protein expression capabilities. * * *

[0159] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and201636318.1 - 37 -modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. REFERENCES

[0160] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

[0161] Bell, A., Brunt, J., Crost, E., Vaux, L., Nepravishta, R., Owen, C. D., … Juge, N. 2019. "Elucidation of a sialic acid metabolism pathway in mucus-foraging Ruminococcus gnavus unravels mechanisms of bacterial adaptation to the gut". Nature Microbiology, 4(12), 2393-2404.

[0162] Bunker, J. J., Drees, C., Watson, A. R., Plunkett, C. H., Nagler, C. R., Schneewind, O., … Bendelac, A.2019. "B cell superantigens in the human intestinal microbiota". Science Translational Medicine, 11(507), eaau9356.

[0163] Frith, M. C., Saunders, N. F. W., Kobe, B., Bailey, T. L. 2008. "Discovering Sequence Motifs with Arbitrary Insertions and Deletions". PLOS Computational Biology, 4(5), e1000071.

[0164] Heap, J. T., Pennington, O. J., Cartman, S. T., Minton, N. P. 2009. "A modular system for Clostridium shuttle plasmids". Journal of Microbiological Methods, 78(1), 79-85. References for Example 5: 1. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009). 2. Mimee, M., Tucker, A. C., Voigt, C. A. & Lu, T. K. Programming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut Microbiota. Cell Syst.1, 62–71 (2015). 3. Heap, J. T., Pennington, O. J., Cartman, S. T. & Minton, N. P. A modular system for Clostridium shuttle plasmids. J. Microbiol. Methods 78, 79–85 (2009). 4. McAllister, K. N., Bouillaut, L., Kahn, J. N., Self, W. T. & Sorg, J. A. Using CRISPR-Cas9-mediated genome editing to generate C. difficile mutants defective in selenoproteins synthesis. Sci. Rep.7, 14672 (2017).201636318.1 - 38 -5. Müh, U., Pannullo, A. G., Weiss, D. S. & Ellermeier, C. D. A Xylose-Inducible Expression System and a CRISPR Interference Plasmid for Targeted Knockdown of Gene Expression in Clostridioides difficile. J. Bacteriol.201, (2019). 6. Tolonen, A. C., Chilaka, A. C. & Church, G. M. Targeted gene inactivation in Clostridium phytofermentans shows that cellulose degradation requires the family 9 hydrolase Cphy3367. Mol. Microbiol.74, 1300–1313 (2009). 7. Cerisy, T. et al. A Targetron-Recombinase System for Large-Scale Genome Engineering of Clostridia. mSphere 4, (2019). 8. Heap, J. T. et al. The ClosTron: Mutagenesis in Clostridium refined and streamlined. J. Microbiol. Methods 80, 49–55 (2010). References for Example 6: 1. Mimee, M., Tucker, A. C., Voigt, C. A. & Lu, T. K. Programming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut Microbiota. Cell Syst.1, 62–71 (2015). 2. Heap, J. T., Pennington, O. J., Cartman, S. T. & Minton, N. P. A modular system for Clostridium shuttle plasmids. J. Microbiol. Methods 78, 79–85 (2009). 3. Müh, U., Pannullo, A. G., Weiss, D. S. & Ellermeier, C. D. A Xylose-Inducible Expression System and a CRISPR Interference Plasmid for Targeted Knockdown of Gene Expression in Clostridioides difficile. J. Bacteriol.201, (2019). 4. McAllister, K. N., Bouillaut, L., Kahn, J. N., Self, W. T. & Sorg, J. A. Using CRISPR-Cas9-mediated genome editing to generate C. difficile mutants defective in selenoproteins synthesis. Sci. Rep.7, 14672 (2017). 5. Sheridan, P. O. et al. Heterologous gene expression in the human gut bacteria Eubacterium rectale and Roseburia inulinivorans by means of conjugative plasmids. Anaerobe 59, 131–140 (2019). 6. Cerisy, T. et al. A Targetron-Recombinase System for Large-Scale Genome Engineering of Clostridia. mSphere 4, (2019). 7. Enyeart, P. J. et al. Generalized bacterial genome editing using mobile group II introns and Cre-lox. Mol. Syst. Biol.9, 1–16 (2013). 8. Heap, J. T. et al. The ClosTron: Mutagenesis in Clostridium refined and streamlined. J. Microbiol. Methods 80, 49–55 (2010). 9. Teufel, F. et al. SignalP 6.0 predicts all five types of signal peptides using protein language models. Nat. Biotechnol. (2022) doi:10.1038 / s41587-021-01156-3.201636318.1 - 39 -

Claims

CLAIMS What is Claimed:

1. A nucleic acid comprising a sequence encoding a molecule of interest and a sequence encoding a signal peptide of one of SEQ ID NOs:1-9.

2. The nucleic acid of claim 1, wherein the molecule of interest comprises a therapeutic protein.

3. The nucleic acid of claim 2, wherein the therapeutic protein comprises IL-10, IL-22, GLP- 2, IL-27, IL-19, IL-20, IL-24, IL-15, IL-2, GMCSF, TNF-alpha, IFN-gamma, CXCL10, CXCL9, hyaluronidase, an anti-TNFalpha antibody, an anti-TNFalpha nanobody, an anti- IL17A antibody, an anti-IL17A nanobody, an anit-alpha4beta7 antibody, an anit- alpha4beta7 nanobody, trefoil factor-3, or a combination thereof.

4. The nucleic acid of any one of claims 1-3, further comprising an inducible promoter.

5. The nucleic acid of claim 4, wherein the inducible promoter comprises pXyl, pBW-EFTU, pAH-EFTU, pER-570, pTet, pAH-570, or a combination thereof.

6. The nucleic acid of any one of claims 1-5, wherein the sequence encoding the molecule of interest and the sequence encoding the signal peptide are separated by a sequence encoding a linker.

7. The nucleic acid of any one of claims 1-5, wherein the sequence encoding the molecule of interest and the sequence encoding the signal peptide are directly adjacent.

8. A genetically modified bacteria comprising the nucleic acid of any one of claims 1-7.

9. The genetically modified bacteria of claim 8, wherein the bacteria comprises a human gut microbiota bacteria.

10. The genetically modified bacteria of claim 8 or 9, wherein the bacteria is a Lachnospiraceae bacteria.

11. The genetically modified bacteria of claim 8 or 9, wherein the bacteria comprises Ruminococcus gnavus and / or Coprococcus comes.

12. A nucleic acid comprising a sequence encoding a protein of interest and a sequence encoding a truncated immunoglobulin binding protein A (IbpA).201636318.1 - 40 -13. The nucleic acid of claim 12, wherein the truncated IbpA protein comprises a peptide of at least 80% identity to amino acids 379-607, 510-607, 560-607, or 585-607 of WP_105084811 IbpA.

14. The nucleic acid of claim 12 or 13, wherein the protein of interest comprises IL-10, IL-22, GLP-2, IL-27, IL-19, IL-20, IL-24, IL-15, IL-2, GMCSF, TNF-alpha, IFN-gamma, CXCL10, CXCL9, hyaluronidase, an anti-TNFalpha antibody, an anti-TNFalpha nanobody, an anti-IL17A antibody, an anti-IL17A nanobody, an anit-alpha4beta7 antibody, an anit-alpha4beta7 nanobody, trefoil factor-3, or a combination thereof.

15. The nucleic acid of any one of claim 12-14, further comprising a signal peptide of one of SEQ ID NOs:1-9.

16. The nucleic acid of any one of claim 12-14, further comprising the nucleic acid of any one of claims 1-7.

17. A genetically modified bacteria comprising the nucleic acid of any one of claims 12-16.

18. The genetically modified bacteria of claim 17, wherein the bacteria comprises a human gut microbiota bacteria.

19. The genetically modified bacteria of claim 17 or 18, wherein the bacteria is a Lachnospiraceae bacteria.

20. The genetically modified bacteria of claim 17 or 18, wherein the bacteria comprises Ruminococcus gnavus and / or Coprococcus comes.

21. A method of increasing secretion of a molecule of interest in a bacteria in a patient, the method comprising administering the nucleic acid of any one of claims 1-7 or claims 12- 16 and / or administering the genetically modified bacteria of any one of claims 8-11 or claims 17-20 to the patient.

22. A method of increasing a molecule of interest in a patient, including increasing the molecule of interest in the gastrointestinal tract of the patient the method comprising administering the nucleic acid of any one of claims 1-7 or claims 12-16 and / or administering the genetically modified bacteria of any one of claims 8-11 or claims 17-20 to the patient.

23. A method of modulating intestinal composition of a patient by increasing a molecule of interest, the method comprising administering the nucleic acid of any one of claims 1-7 or201636318.1 - 41 -claims 12-16 and / or administering the genetically modified bacteria of any one of claims 8-11 or claims 17-20 to the patient.

24. A method of treating a patient, including treating a gastrointestinal disorder in the patient, the method comprising administering nucleic acid of any one of claims 1-7 or claims 12- 16 and / or administering the genetically modified bacteria of any one of claims 8-11 or claims 17-20 to the patient, wherein the patient is in need of a molecule of interest.

25. The method of any one of claims claim 21-24, wherein the molecule of interest comprises a cytokine, an antibody, a metabolite, or a molecule that is decreased in a gastrointestinal disorder.

26. The method of any one of claims claim 21-25, wherein the molecule of interest comprises IL-10, IL-22, GLP-2, IL-27, IL-19, IL-20, IL-24, IL-15, IL-2, GMCSF, TNF-alpha, IFN- gamma, CXCL10, CXCL9, hyaluronidase, an anti-TNFalpha antibody, an anti-TNFalpha nanobody, an anti-IL17A antibody, an anti-IL17A nanobody, an anit-alpha4beta7 antibody, an anit-alpha4beta7 nanobody, trefoil factor-3, or a combination thereof.

27. A method of engineering a bacteria, the method comprising performing at least one of the following steps, which may be in any order: (a) obtaining a recipient bacteria; (b) resuspending a donor bacteria comprising a nucleic acid of interest in the recipient bacteria; (c) mating the donor bacteria and recipient bacteria to generate mated bacteria; (d) plating the mated bacteria on selective media; (e) isolating single colonies of the mated bacteria; (f) grow the isolated single colonies in media; and (g) subculture the isolated single colonies with inducers.

28. The method of claim 27, wherein the nucleic acid of interest comprises a plasmid of interest.

29. The method of claim 28, wherein the nucleic acid of interest encodes for a molecule of interest.

30. The method of claim 29, wherein the molecule of interest comprises a signal peptide of one of SEQ ID NOs:1-9.201636318.1 - 42 -31. The method of claim 29 or 30, wherein the molecule of interest comprises a truncated IbpA protein.

32. The method of any one of claims 29-31, wherein the plasmid of interest comprises an inducible promoter.

33. The method of any one of claims 27-32, wherein the donor bacteria is E. coli.

34. The method of any one of claims 27-33, wherein the recipient bacteria is a Lachnospiraceae bacteria.

35. The method of any one of claims 27-34, wherein the media of (f) does not comprise E. coli.

36. A genetically modified bacteria comprising an exogenous nucleic acid encoding a cytokine, wherein the bacteria is a Lachnospiraceae species.

37. The genetically modified bacteria of claim 36, wherein the Lachnospiraceae species is a Ruminococcus gnavus species.

38. The genetically modified bacteria of claim 36, wherein the Lachnospiraceae species is a Lachnoclostridium symbiosum species.

39. The genetically modified bacteria of claim 36, wherein the Lachnospiraceae species is a Coprococcus comes species.

40. The genetically modified bacteria of any one of claims 36 to 39, wherein the cytokine is an IL-22 cytokine 41. The genetically modified bacteria of any one of claims 36 to 39, wherein the cytokine is an IL-10 cytokine.

42. The genetically modified bacteria of any one of claims 36 to 41, wherein the exogenous nucleic acid is integrated into the genetically modified bacteria’s genome.

43. The genetically modified bacteria of any one of claims 36 to 42, wherein the genetically modified bacteria is capable of secreting the cytokine.

44. The genetically modified bacteria of any one of claims 36 to 43, wherein the exogenous nucleic acid further comprises an inducible promoter.

45. The genetically modified bacteria of claim 44, wherein the inducible promoter is a tetracycline inducible promoter.201636318.1 - 43 -46. The genetically modified bacteria of any one of claims 36 to 45, wherein the exogenous nucleic acid further comprises a signal peptide of one of SEQ ID NOs:1-9.

47. A genetically modified bacteria comprising an exogenous nucleic acid encoding a nanobody, wherein the bacteria is a Lachnospiraceae species.

48. The genetically modified bacteria of claim 47, wherein the Lachnospiraceae species is a Ruminococcus gnavus species.

49. The genetically modified bacteria of claim 47, wherein the Lachnospiraceae species is a Lachnoclostridium symbiosum species.

50. The genetically modified bacteria of claim 47, wherein the Lachnospiraceae species is a Coprococcus comes species.

51. The genetically modified bacteria of any one of claims 47 to 50, wherein the nanobody is an anti-TNFα nanobody.

52. The genetically modified bacteria of any one of claims 47 to 51, wherein the exogenous nucleic acid is integrated into the genetically modified bacteria’s genome.

53. The genetically modified bacteria of any one of claims 47 to 52, wherein the genetically modified bacteria is capable of secreting the nanobody.

54. The genetically modified bacteria of any one of claims 47 to 53, wherein the exogenous nucleic acid further comprises an inducible promoter.

55. The genetically modified bacteria of claim 54, wherein the inducible promoter is a tetracycline inducible promoter.

56. The genetically modified bacteria of any one of claims 47 to 55, wherein the exogenous nucleic acid further comprises a signal peptide of one of SEQ ID NOs:1-9.

57. A culture system comprising the genetically modified bacteria of any one of claims 8 to 11, 17 to 20, or 36 to 56 comprised in culture media.

58. The culture system of claim 57, wherein the culture media comprises brain heart infusion media.

59. A supernatant collected from the culture system of claim 57 or 58.201636318.1 - 44 -

Citation Information

Patent Citations

  • Intramolecular Trans-Sialidase

    US20190037899A1

  • Surface display of proteins on recombinant bacteria and uses thereof

    US20210369836A1